Bonefos ampoules 60mg 5ml №5

Release form

Concentrate for solution for intravenous administration

Packaging

5 pieces

Mechanism of action

Bonefos has the effect of normalizing the Calcium content in the bone tissue, inhibiting bone resorption

Indications

Hypercalcemia due to malignant tumors;
osteolytic metastases of malignant tumors and myeloma (multiple myeloma);
prevention of the development of bone metastases of primary breast cancer.

Contraindications

Hypersensitivity to clodronic acid, other bisphosphonates, or any components that make up the preparation; pregnancy; breastfeeding period; concomitant therapy with other bisphosphonates;
children's age (there is no clinical experience).

Special notes

Bonefos should not be taken with milk, food, or with preparations containing calcium or other divalent cations, since they all interfere with the absorption of clodronate. The prepared solution for infusion should be used within 12 hours.

Composition

Disodium clodronate tetrahydrate

Dosage and administration

With hypercalcemia, 2400-3200 mg / day in 2 divided doses with a gradual decrease to a maintenance dose of 1600 mg / day; osteolytic bone changes,caused by malignant tumors without hypercalcemia - the initial dose of 1600 mg / day, if necessary - up to 3600 mg / day (no more); in patients with signs of renal failure - no more than 1600 mg.

Storage conditions

In a dry, dark place at a temperature of no higher than 25 ° C.

Shelf life

5 years

Prescription doctor